Nimotuzumab Prolongs Survival in Patients With Malignant Gliomas: A Phase I/Ii Clinical Study of Concomitant Radiochemotherapy With or Without Nimotuzumab

Experimental and Therapeutic Medicine - Greece
doi 10.3892/etm.2012.555
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Pcn65 - Long- Term Survival Among Patients With High-Grade Glioma Treated With Nimotuzumab

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn156 - Pharmacoeconomics of Nimotuzumab in Patients With Head and Neck Cancer in Cuba

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

640. AdCD40L Immunostimulatory Gene Therapy in Combination With Cyclophosphamide Prolongs 6-Months Survival in a Phase I/Ii Trial for Malignant Melanoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Clinical Efficacy and Safety of Nimotuzumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer: A Retrospective Analysis

Journal of International Medical Research
BiochemistryMedicineCell Biology
2020English

Phase II Trial of Karenitecin in Patients With Malignant Melanoma: Clinical and Translational Study

Clinical Cancer Research
Cancer ResearchOncology
2005English

A Phase I Trial of Enzastaurin in Patients With Recurrent Gliomas

Clinical Cancer Research
Cancer ResearchOncology
2009English

A Phase I/Ii Study of Lomustine and Temozolomide in Patients With Cerebral Metastases From Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
2006English

Experience With Combination of Nimotuzumab and Intensity-Modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2015English

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy